- Home
- EML vs KLTOW Comparison
EML vs KLTOW Comparison
Compare EML & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- KLTOW
- Stock Information
- Founded
- EML 1858
- KLTOW N/A
- Country
- EML United States
- KLTOW United States
- Employees
- EML N/A
- KLTOW 3
- Industry
- EML Industrial Machinery/Components
- KLTOW Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EML Consumer Discretionary
- KLTOW Health Care
- Exchange
- EML Nasdaq
- KLTOW Nasdaq
- Market Cap
- EML 141.7M
- KLTOW N/A
- IPO Year
- EML N/A
- KLTOW 2022
- Fundamental
- Price
- EML $23.70
- KLTOW $0.24
- Analyst Decision
- EML
- KLTOW
- Analyst Count
- EML 0
- KLTOW 0
- Target Price
- EML N/A
- KLTOW N/A
- AVG Volume (30 Days)
- EML 12.4K
- KLTOW N/A
- Earning Date
- EML 08-05-2025
- KLTOW N/A
- Dividend Yield
- EML 1.86%
- KLTOW N/A
- EPS Growth
- EML N/A
- KLTOW N/A
- EPS
- EML N/A
- KLTOW N/A
- Revenue
- EML $271,440,503.00
- KLTOW N/A
- Revenue This Year
- EML $1.56
- KLTOW N/A
- Revenue Next Year
- EML $7.00
- KLTOW N/A
- P/E Ratio
- EML $11.29
- KLTOW N/A
- Revenue Growth
- EML 8.15
- KLTOW N/A
- 52 Week Low
- EML $19.06
- KLTOW N/A
- 52 Week High
- EML $35.03
- KLTOW N/A
- Technical
- Relative Strength Index (RSI)
- EML 56.10
- KLTOW N/A
- Support Level
- EML $21.78
- KLTOW N/A
- Resistance Level
- EML $23.83
- KLTOW N/A
- Average True Range (ATR)
- EML 0.58
- KLTOW 0.00
- MACD
- EML 0.02
- KLTOW 0.00
- Stochastic Oscillator
- EML 93.66
- KLTOW 0.00
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.